Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases, particularly cholestatic liver and bile acid disorders. Its core products include LIVMARLI, CHOLBAM, and CHENODAL, targeting conditions like Alagille syndrome, PFIC, and CTX. The company leverages proprietary drug candidates, licensing agreements, and strategic acquisitions to address high unmet medical needs in niche markets worldwide.
This description was generated via AI from an annual report. Updated about 1 year ago.